1. Academic Validation
  2. Targeting glucose metabolism to develop anticancer treatments and therapeutic patents

Targeting glucose metabolism to develop anticancer treatments and therapeutic patents

  • Expert Opin Ther Pat. 2022 Apr;32(4):441-453. doi: 10.1080/13543776.2022.2027912.
Yan Zhou 1 Yizhen Guo 1 Kin Yip Tam 1
Affiliations

Affiliation

  • 1 Faculty of Health Sciences, University of Macau, Avenida de Universidade, Taipa, Macau SAR, PR China.
Abstract

Introduction: One of the most distinctive hallmarks of Cancer cells is increased glucose consumption for aerobic glycolysis, which is called the Warburg effect. In recent decades, extensive research has been carried out to exploit this famous phenomenon, trying to detect promising targetable vulnerabilities in altered metabolism to fight Cancer. Targeting aberrant glucose metabolism can perturb Cancer malignant proliferation and even induce programmed cell death.

Areas covered: This review covered the recent patents which focused on targeting key glycolytic Enzymes, including Hexokinase, pyruvate dehydrogenase kinases, and Lactate Dehydrogenase for Cancer treatment.

Expert opinion: Compared with the conventional Cancer treatment, specifically targeting the well-known Achilles heel, the Warburg effect has attracted considerable attention. Although there is still no single glycolytic agent for clinical Cancer treatment, the combination of glycolytic inhibitor with conventional Anticancer drugs or the combined use of multiple glycolytic inhibitors are being investigated extensively in recent years, which could emerge as attractive Anticancer strategies.

Keywords

Cancer treatment patent; Warburg effect; cancer glucose metabolism; glycolytic inhibitor; hexokinase 2 (HK2); lactate dehydrogenase A (LDHA); pyruvate dehydrogenase kinase (PDK).

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-100017
    99.67%, GLUT1 Inhibitor